Mirum Pharmaceuticals Inc. (NASDAQ:MIRM) is one of the best biotech stocks to buy according to Wall Street analysts. On December 8, Baird reiterated its Outperform rating on Mirum Pharmaceuticals Inc. (NASDAQ:MIRM) and raised the price target to $88 from $80. Baird Lifts Mirum Pharmaceuticals, Inc. (MIRM) Price Target on Bluejay Therapeutics Acquisition Copyright: zneb076 / 123RF Stock Photo The price target hike follows the company’s agreement to acquire Bluejay Therapeutics for $620 million in cash. W ...

Mirum Pharmaceuticals Inc. (NASDAQ:MIRM) is one of the high short interest stocks to buy right now. On December 9, Morgan Stanley analyst Michael Ulz raised the firm’s price target on Mirum Pharmaceuticals to $95 from $81 with an Overweight rating on the shares. Ulz informed investors that the acquisition of Bluejay is significant because it adds the drug brelovitug to the pipeline. Brelovitug has shown promising activity and tolerability in treating hepatitis delta virus and will expand the company’s rare ...